Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.571 USD | +0.18% | -16.03% | -46.13% |
05:43pm | Ensysce Biosciences Back in Compliance With Nasdaq | MT |
May. 20 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 1.2M | Sales 2025 * | 12.51M | Capitalization | 4.32M |
---|---|---|---|---|---|
Net income 2024 * | -19M | Net income 2025 * | -8M | EV / Sales 2024 * | 3.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.35 x |
P/E ratio 2024 * |
-0.38
x | P/E ratio 2025 * |
-0.66
x | Employees | 7 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.7% |
Latest transcript on Ensysce Biosciences, Inc.
1 day | +1.58% | ||
1 week | -14.63% | ||
Current month | -1.88% | ||
1 month | -2.11% | ||
3 months | -36.63% | ||
6 months | -29.12% | ||
Current year | -45.24% |
Managers | Title | Age | Since |
---|---|---|---|
D. Kirkpatrick
CEO | Chief Executive Officer | 67 | 08-12-31 |
David Humphrey
DFI | Director of Finance/CFO | 55 | 21-01-31 |
Jeffrey Millard
COO | Chief Operating Officer | 49 | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Martin
BRD | Director/Board Member | 63 | 19-12-31 |
D. Kirkpatrick
CEO | Chief Executive Officer | 67 | 08-12-31 |
Bob Gower
CHM | Chairman | 86 | 07-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 0.571 | +0.18% | 54 265 |
24-05-24 | 0.57 | -3.19% | 111,371 |
24-05-23 | 0.5888 | -7.54% | 232,214 |
24-05-22 | 0.6368 | -6.35% | 107,448 |
24-05-21 | 0.68 | -7.98% | 159,317 |
Delayed Quote Nasdaq, May 28, 2024 at 01:32 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.24% | 4.32M | |
+50.84% | 63.85B | |
-2.21% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.63% | 26.52B | |
-21.59% | 18.69B | |
+3.10% | 12.73B | |
+22.07% | 12.11B | |
+27.97% | 12.07B |
- Stock Market
- Equities
- ENSC Stock